IRWD
- Ironwood Pharmaceuticals, Inc.
()
Overview
Company Summary
Ironwood Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative medicines. With its headquarters in Cambridge, Massachusetts, Ironwood primarily operates in the United States.
The company specializes in the discovery, development, and marketing of differentiated medicines targeting gastrointestinal diseases. Ironwood's core areas of expertise include the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation, which are commonly experienced digestive disorders affecting millions of people worldwide.
Ironwood is known for its flagship product, Linzess (linaclotide), which is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with IBS-C and chronic idiopathic constipation. Linzess works by increasing fluid secretion in the intestines, which helps to ease constipation and alleviate symptoms associated with these conditions.
In addition to Linzess, Ironwood has a diverse pipeline of potential therapeutic options focused on gastrointestinal disorders, including novel drug candidates for other forms of irritable bowel syndrome, refractory gastroesophageal reflux disease, and abdominal pain syndromes.
Apart from its pharmaceutical endeavors, Ironwood Pharmaceuticals also maintains a collaborative research and development partnership with another pharmaceutical company, AstraZeneca. The aim of this partnership is to develop and commercialize a fixed-dose combination product incorporating Linzess and AstraZeneca's investigational compound, for the treatment of symptoms related to cardiovascular and metabolic diseases.
Overall, Ironwood Pharmaceuticals is dedicated to addressing unmet medical needs in the field of gastrointestinal diseases, leveraging its expertise in research, development, and commercialization to improve the lives of patients suffering from these conditions.